Revenue growth of 10% in H2 brought FY results in line and the company was looking well set for strong progress in FY20. However, Covid-19 presents a significant short term challenge, given SUN’s focus on elective surgeries. The Board has moved quickly to enact cash preserving and cost saving measures, whilst continuing to supply essential products. Cash on the balance sheet and support from the group’s bankers provides short term liquidity and other indications of financial suppo
31 Mar 2020
FY19 prelims & Covid-19 update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY19 prelims & Covid-19 update
Surgical Innovations Group plc (SUN:LON) | 0.5 0 (-9.1%) | Mkt Cap: 4.66m
- Published:
31 Mar 2020 -
Author:
Chris Glasper -
Pages:
3
Revenue growth of 10% in H2 brought FY results in line and the company was looking well set for strong progress in FY20. However, Covid-19 presents a significant short term challenge, given SUN’s focus on elective surgeries. The Board has moved quickly to enact cash preserving and cost saving measures, whilst continuing to supply essential products. Cash on the balance sheet and support from the group’s bankers provides short term liquidity and other indications of financial suppo